MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
9.12
-0.62 (-6.37%)
At close: Mar 16, 2026, 4:00 PM EDT
9.04
-0.08 (-0.88%)
Pre-market: Mar 17, 2026, 8:41 AM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 8 or -25.81% compared to the previous year.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
n/a
Profits / Employee
-$537,185
Market Cap
42.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Palatin Technologies | 29 |
| Lisata Therapeutics | 26 |
| Plus Therapeutics | 21 |
| Edesa Biotech | 17 |
| Atossa Therapeutics | 15 |
| Apollomics | 13 |
| Nutriband | 13 |
INKT News
- 6 days ago - Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
- 6 days ago - MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Benzinga
- 7 days ago - MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - GlobeNewsWire
- 5 weeks ago - MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - GlobeNewsWire
- 2 months ago - MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - GlobeNewsWire
- 4 months ago - MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - GlobeNewsWire
- 4 months ago - MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 - GlobeNewsWire